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BACKGROUND: The development of androgen independence, chemo-, and radioresistance are critical markers of prostate cancer
progression and the predominant reasons for its high mortality. Understanding the resistance to therapy could aid the development
of more effective treatments.
AIM: The aim of this study is to investigate the effects of insulin-like growth factor-binding protein-2 (IGFBP-2) on prostate cancer cell
proliferation and its effects on the response to docetaxel.
METHODS: DU145 and PC3 cells were treated with IGFBP-2, insulin-like growth factor I (IGF-I) alone or in combination with blockade
of the IGF-I receptor or integrin receptors. Cells were also treated with IGFBP-2 short interfering ribonucleic acid with or without a
PTEN (phosphatase and tensin homologue deleted on chromosome 10) inhibitor or docetaxel. Tritiated thymidine incorporation
was used to measure cell proliferation and Trypan blue cell counting for cell death. Levels of IGFBP-2 mRNA were measured using
RT–PCR. Abundance and phosphorylation of proteins were assessed using western immunoblotting.
RESULTS: The IGFBP-2 promoted cell growth in both cell lines but with PC3 cells this was in an IGF-dependent manner, whereas with
DU145 cells the effect was independent of IGF receptor activation. This IGF-independent effect of IGFBP-2 was mediated by
interaction with b-1-containing integrins and a consequent increase in PTEN phosphorylation. We also determined that silencing
IGFBP-2 in both cell lines increased the sensitivity of the cells to docetaxel.
CONCLUSION: The IGFBP-2 has a key role in the growth of prostate cancer cells, and silencing IGFBP-2 expression reduced the
resistance of these cells to docetaxel. Targeting IGFBP-2 may increase the efficacy of docetaxel.
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About 11.9% of cancers in men are due to prostate adenocarci-
noma (CaP) and its incidence and prevalence are increasing
(Ferlay et al, 2010). Androgen deprivation therapy is the mainstay
for treating locally advanced, metastatic or recurrent disease.
Development of androgen independence (AI), chemo- and radio-
resistance are critical markers of progression, and the predomi-
nant reason for its high cancer-related mortality. When AI occurs,
docetaxel-based chemotherapy is one of the few treatment options
available. Hence, many are endeavouring to identify molecular
factors that could mediate progression to therapy resistance and
more lethal metastatic disease. The insulin-like growth factor (IGF)
axis, which consists of two ligands (IGF-I and IGF-II) that
principally signal via the type 1 IGF receptor (IGF-IR) and a
family of six high-affinity IGF-binding proteins (IGFBPs), has an
important role in cancer (Pollak, 2008). Research has clearly
established that the IGF axis has a very important role in the
development and progression of many epithelial cancers, including
prostate (Meinbach and Lokeshwar, 2006). At the cellular level the
IGF-I receptor appears to have a fundamental role in maintaining
the transformed phenotype for many cancer cells (Baserga et al,
2003). Recent prospective epidemiology has consistently shown
strong associations between circulating IGF-I levels and the
subsequent risk of developing prostate cancer (Roddam et al,
2008). Individuals with circulating IGF-I levels within the upper
end of the normal range are at significantly increased risk of
subsequently developing CaP years later. The actions of the IGFs
are modulated by a family of high-affinity IGF-binding proteins
(IGFBPs 1–6); IGFBPs function to regulate IGF-I- and IGF-II-
induced cell signalling in complex ways that involve both
inhibiting as well as promoting IGF action. IGF-independent
actions of IGFBPs have also been recognised, indicating that
IGFBPs can intrinsically modulate aspects of cell growth and
survival (Holly and Perks, 2006). The IGFBP-2 is considered a key
factor in prostate cancer progression (Degraff et al, 2009) with
levels of IGFBP-2 being elevated in patients with CaP, both in
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sserum where levels correlate with those of PSA (Kanety et al, 1993)
and in the tumours (Bubendorf et al, 1999). Serum levels are also
associated with prognosis (Inman et al, 2005). We recently made
the novel observation that IGFBP-2 can intrinsically regulate the
tumour suppressor gene, PTEN (phosphatase and tensin homo-
logue deleted on chromosome 10; Perks et al, 2007). PTEN is a
phosphoprotein with dual-function protein and lipid phosphatase
activity that dephosphorylates the products of phosphatidyl-
inositol 3-kinase (PI3K) and focal adhesion kinase and suppresses
PI3K/Akt and mitogen-activated protein kinase signalling (Tamura
et al, 1999; Dahia, 2000; Cully et al, 2006), thereby opposing the
survival and proliferative actions of many growth factors. PTEN
also has an important role in CaP progression, and global
expression profiling identified IGFBP-2 as the most significant
biomarker for tumour PTEN status (Mehrian-Shai et al, 2007). We
have investigated the effects of IGFBP-2 on CaP cell proliferation
and on the response to docetaxel; as loss of PTEN is a common
cause of CaP progression, we examined both DU145 cells in which
PTEN is functional and PC3 cells which lack functional PTEN.
MATERIALS AND METHODS
Materials
All chemicals and inhibitors were from Sigma-Aldrich (Dorset,
UK) unless stated otherwise. Human, recombinant IGF-I and
IGFBP-2 peptides were from Gropep (Adelaide, Australia); IGFBP-2
short interfering ribonucleic acid (siRNA) and random sequence-
negative control siRNA were from Qiagen Ltd (Crawley, West
Sussex, UK). The human b1-integrin receptor blocking antibody
was from Chemicon (Hampshire, UK), and the control mouse IgG
antibody was from Dako (Cambridgeshire, UK). A PTEN inhibitor,
bpV(HOpic), was from Calbiochem (Nottingham, UK). Tissue
culture plastics were from Greiner Labortechnik Ltd (Tyne and
Wear, UK). The enhanced chemiluminescence reagents were from
Amersham International (Little Chalfont, UK). The BCA protein
assay reagent kit was purchased from Pierce (Rockford, IL, USA).
Cell culture
DU145 (PTENþ) and PC3 (PTEN ) androgen-independent
prostate cancer cells were grown and maintained as described
previously (Thomas et al, 2009).
Trypan blue cell counting and tritiated thymidine incorporation
were carried out as described previously (Thomas et al, 2009,
2010).
Transfection with siRNA
CaP cells were placed in 24 well plates (8 10
4 cells per well) in
growth media and transfected with siRNA (50nM final concentra-
tion) for IGFBP-2 or with a random sequence negative control
siRNA at the same concentration. At 24h after transfection, cells
were then washed with PBS and placed in serum-free media (SFM)
for appropriate lengths of time (as described in figure legends)
before dosing.
Western immunoblotting (WIB)
Cells were lysed as described previously (Thomas et al, 2010),
while conditioned SFM were collected and concentrated using
centrifugal filter devices (Millipore, Watford, UK). Lysates were
loaded according to protein concentration and equal volumes of
supernatants were assessed (to ensure that changes in abundance
were not because of the changes in total cell number). The samples
were processed as described previously (Thomas et al, 2010).
Nonspecific binding sites on the membranes were blocked for a
minimum of 2h with either 5% (w/v) milk in Tris-buffered saline/2%
Tween (TBST) for probing with anti-GAPDH (1:5000) anti-tubulin
(1:1500; Chemicon) anti-IGFBP-2 (1:1000; Santa Cruz Biotech-
nology, Heidelberg, Germany) anti-PTEN (1:750) or 3% BSA for
probing with anti-phospho PTEN (1:1000; both from
New England Biolabs, Herts, UK). After the removal of excess
unbound primary antibody with three TBST washes, appropriate
secondary antibodies conjugated to peroxidase were added for 1h.
Peroxidase binding was visualised by enhanced chemilumines-
cence and detected as described previously (Thomas et al, 2010).
RT–PCR
After extracting RNA from cells with Trizol reagent according to
manufacturers’ instructions (Invitrogen, Paisley, UK), total RNA
(0.5mg) was used for cDNA synthesis using Superscript III First-
Strand cDNA synthesis kit (Invitrogen) with random hexamers.
RT–PCR was performed to detect mRNA expression of IGFBP-2
gene. PCR was carried out in a total volume of 10 ml, using 1 mlo f
cDNA, 0.25 units Taq DNA polymerase, 2.0mM MgCl2, 0.1mM
dNTPs and 0.25mM of primers. Primer pairs for IGFBP-2 were
designed with online software ‘OligoPerfect Designer’ (Invitrogen).
The sense primer for IGFBP-2 was (50-CCTCAAGTCG
GGTATGAAGG-30) and the antisense primer was (50-ACCTGG
TCCAGTTCCTGTTG-30). The expected amplified fragment for
IGFBP-2 was 162bp. A housekeeping gene, GAPDH, was used as an
internal control, the sense primer for GAPDH gene was (50-A
CAGTCAGCCGCATCTTC-30), and the antisense primer was (50-G
ACAAGCTTCCCGTTCTCAG-30). The expected amplified fragment
for GAPDH was 259bp. PCR conditions were 941C for 5min,
followed by 28 cycles at 941C for 30s, 601C for for 1min and 721C
for 45s with final extension at 721C for 10min. The amplified DNA
products were separated on a 2% agarose gel, stained with
ethidium bromide, visualised with an ultraviolet transilluminator.
Data analysis
Data were analysed with SPSS 12.0.1 for Windows using one-way
ANOVA applying post hoc least significant difference. A statisti-
cally significant difference was present at Po0.05.
RESULTS
Effects of IGFBP-2 on the proliferation of prostate cancer
cells
Addition of IGFBP-2 caused a dose-dependent increase in tritiated
thymidine uptake in DU145 cells after 48h, with significant effects
occurring from 62.5ngml
 1 IGFBP-2 (Po0.05; Figure 1A). This
effect was also seen with PC3 cells (Figure 1B). Cell counting
produced a similar trend in each of these cell lines (data
not shown).
Is IGFBP-2-induced proliferation dependant on the IGF-I
receptor?
We treated both cell lines with a proliferative dose of either IGF-I
or IGFBP-2 in the presence or absence of an IGF-IR tyrosine kinase
inhibitor, AG1024 (1mM), which we have shown previously is
effective in these cells (Thomas et al, 2010). With DU145 cells, IGF-I
and IGFBP-2 each induced a significant increase in cell growth
(Po0.001). AG1024 blocked the response to IGF-I but not that to
IGFBP-2 (Figure 1C). With PC3 cells, IGF-I and IGFBP-2 each
induced a significant increase in cell growth (Po0.001; Po0.05,
respectively) but in contrast to the DU145 cells, AG1024 blocked
the response to both peptides (Figure 1D). This suggested that
IGFBP-2 was increasing cell proliferation in an intrinsic, IGF-
independent manner in DU145 cells but in an IGF-dependent way
in the PC3 cells.
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sInvolvement of integrin receptors in the intrinsic effects of
IGFBP-2 in DU145 cells
We tested the effect of a short disintegrin, RGD containing,
peptide, which represents an amino acid sequence common to
several ECM components that bind to integrins. We observed a
dose-dependent decrease in total cell number with increasing RGD
peptide concentrations (0–40mgml
 1; Figure 2A). We found that
there was no increase in IGFBP-2 mRNA. However, conditioned
media from this experiment showed a progressive increase in
levels of IGFBP-2 with increasing RGD peptide concentration
(Figure 2A insert), suggesting displacement of IGFBP-2 from the cell
surface as opposed to an increase in its synthesis. We anticipated
that the increase in IGFBP-2 in the cell supernatants would be
accompanied by a decrease in the cell lysates. However, levels of
IGFBP-2 in the cell lysate remained the same suggesting that the
association of the RGD peptide with the cell surface was in some way
inhibiting degradation of IGFBP-2. We went on to show that the
proliferative effect of exogenous IGFBP-2 was markedly inhibited in
t h ep r e s e n c eo fas u b - a p o p t o t i cd o s eo fR G Dp e p t i d e( F i g u r e2 B ) .
This indicated that IGFBP-2 was promoting growth via interaction
with an integrin receptor. We then showed that IGFBP-2 acted
specifically via integrin receptors containing the b1 subunit, as a
b1-integrin receptor blocking antibody similarly inhibited cell
proliferation stimulated by exogenous IGFBP-2, whereas a control
mouse IgG1 antibody was without effect (Figure 2C).
Involvement of PTEN in the intrinsic effects of IGFBP-2 in
DU145 cells
We observed that exogenous IGFBP-2 was associated with
increased PTEN phosphorylation but without affecting total PTEN
abundance. This occurred as early as 10min (data not shown)
following treatment with IGFBP-2 and was sustained for 48h. With
IGFBP-2 being able to induce a 41% (Po0.05) increase in
phosphorylated PTEN at 48h (Figure 3A). We established that
IGFBP-2 siRNA effectively reduced endogenous levels of IGFBP-2
mRNA and protein, and this correlated with a reduction in
tritiated thymidine incorporation, which could be abrogated by
adding back exogenous IGFBP-2 (Figure 3B). We also demon-
strated that the cell growth inhibitory effect of IGFBP-2 siRNA was
reduced in the presence of a specific PTEN inhibitor (0.1mM), from
47% down to 23% (Po0.001), suggesting that this growth
inhibition at least partially involved increased PTEN activity
( F i g u r e3 C ) .W eh a v ee f f e c t i v e l yu s e dt h i sP T E Ni n h i b i t o rp r e v i o u s l y
(Perks et al, 2007), and we confirmed that it was effective in this cell
line by showing that the IGF-II-induced activation of p-Akt was
increased in the presence of the PTEN inhibitor (data not shown).
To delineate that PTEN was downstream of IGFBP-2 binding to the
b1-integrin receptor, we examined PTEN phosphorylation following
exposure to IGFBP-2 with or without cells being pre-dosed with the
b1-integrin-receptor-blocking antibody. With IGFBP-2 alone, there was
an increase in PTEN phosphorylation, the blocking antibody had no
effect alone but blocked the IGFBP-2-induced increase in PTEN
phosphorylation (Figure 3D). These findings are consistent with IGFBP-
2 acting on DU145 cells in an IGF-independent manner via b1-integrin-
receptor-mediated inactivation of PTEN via its phosphorylation.
Does IGFBP-2 affect sensitivity of CaP to docetaxel-
induced cell death?
We found that docetaxel induced a significant increase in
cell death with DU145 cells (Po0.001) and with PC3 cells
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Figure 1 Effects of IGFBP-2 on the proliferation of prostate cancer cells. (A and B) Graphs show TTI for DU145 (A) and PC3 (B) cells (0.25 10
5 per
well; 24-well plates) treated for 48h with increasing concentrations of IGFBP-2 (0–1000ngml
 1) after initial plating in GM for 24h and serum starving for a
further 24h. (C and D) Graph shows total cell number of DU145 (C) and PC3 (D) cells (0.2 10
6 per well; six-well plates) pre-dosed for 1h with 1mM of
AG1024–IGF-IR tyrosine kinase inhibitor or SFM. Cells were then spiked with IGF-I (125ngml
 1) or IGFBP-2 (250ngml
 1) for 48h after initial plating in
GM for 24h and serum starving for a further 24h. Graphs are representative of experiments repeated three times showing the mean±s.e.m.
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s(Po0.001) (Figures 4A and B, respectively). The induced cell
death was unaffected in the presence of the control, non-silencing
siRNA; however, with IGFBP-2 knock down, the response
of the cells to docetaxel was increased significantly (Po0.001
for both). With DU145 cells docetaxel-induced death increased
1.95-fold and with PC3 cells the induced death increased
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Figure 2 Involvement of integrin receptors in the intrinsic effects of IGFBP-2 on DU145 cells. (A) Graph shows total cell number of DU145 cells following
treatment with RGD peptide (0–40mgml
 1) for 48h after initial plating (as in Figures 1A and B) in GM for 24h and serum starving for a further 24h. Insert
shows a representative PCR blot (of IGFBP-2m RNA) and WIBs (of IGFBP-2 protein from cell lysates and conditioned cell supernatants). A WIB for tubulin
is also shown as a loading control for IGFBP-2 in the cell lysates. (B) Graph shows total cell number of DU145 cells pre-dosed for 1h with RGD peptide
(40mgml
 1) or SFM and then re-dosed with SFM or IGFBP-2 (250ngml
 1) for 48h after initial plating (as in Figures 1C and D) in GM for 24h and serum
starving for a further 24h. (C) Graph shows total cell number of DU145 cells pre-dosed for 1h with b1-integrin receptor-blocking antibody (200ngml
 1)o r
control mouse IgG1 antibody (200ngml
 1) or SFM before they were then spiked with IGFBP-2 (250ngml
 1) for 48h after initial plating (as in Figures 1C
and D) in GM for 24h and serum starving for a further 24h. All graphs show the mean±s.e.m. of at least three independent experiments each repeated in
triplicate.
Figure 3 Involvement of PTEN in the intrinsic effects of IGFBP-2 in DU145 cells. (A) DU145 cells were seeded (0.25 10
6/T25 flask) in GM for 24h,
serum starved for a further 24h before re-dosing with SFM or IGFBP-2 (250ngml
 1) for 24 and 48h and then lysed. A representative WIB (repeated at
least three times) for phospho-PTEN, PTEN and GAPDH are shown. The mean±s.e.m. optical densitometry measurements of the three separate
experiments are indicated. (B) DU145 cells were seeded in GM (0.08 10
6 per well; 24-well plates) and transfected with either IGFBP-2 siRNA (50nM)o r
random sequence siRNA (50nM) for 24h and then following 4h in SFM were spiked with or without exogenous IGFBP-2 (250ngml
 1) followed by a
further 20h in SFM before assessment of total cell number. Graph represents the mean±s.e.m. of three individual experiments each repeated in triplicate.
Insert (B) shows a representative WIB for IGFBP-2 and tubulin protein and RT–PCR for IGFBP-2 mRNA from DU145 cell lysates treated as in B.( C)
DU145 cells were seeded in GM (0.08 10
6 per well; 24-well plates) and transfected as in (B) for 24h and then following 4h in SFM were spiked with or
without a PTEN inhibitor, bpV(HOpic), (0.1mM) followed by a further 20h in SFM before cell counting. Graph represents the mean±s.e.m. of three
individual experiments each repeated in triplicate. (D) DU145 cells were seeded in GM (0.2 10
6 per well; six-well plates) and subjected to SFM conditions
for 24h before pre-dosing for 1h with a b1-integrin-receptor-blocking antibody (200ngml
 1) or SFM before they were then spiked with IGFBP-2
(250ngml
 1) for 48h. Whole-cell lysates were subjected to western immunoblotting for phosphor-PTEN and GAPDH. A representative blot of
experiments repeated three times is shown.
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s1.47-fold. The insert to Figure 4B shows a WIB for IGFBP-2
illustrating effective silencing in PC3 cells. These data showed that
removing IGFBP-2 increased the effect of docetaxel to induce CaP
cell death.
DISCUSSION
The development of AI and resistance to therapy remains a
challenging issue in the management of prostate cancer. There is
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stherefore a great need for a better understanding of the
mechanisms contributing to this progression and identification
of new therapeutic targets that may improve effective treatment.
One of the established factors that frequently contributes to
disease progression is the loss of the tumour suppressor PTEN
(Uzoh et al, 2009). A screen for markers of PTEN identified IGFBP-2
as being the most significantly associated marker (Mehrian-Shai
et al, 2007). In addition, there is accumulating evidence that
IGFBP-2 may have an important role in prostate cancer progres-
sion (Degraff et al, 2009). Expression of IGFBP-2 has also been
reported to increase following castration and to promote the
growth of androgen-independent prostate cancer cells (Kiyama
et al, 2003).
We have confirmed that IGFBP-2 promoted the growth of
DU145 prostate cancer cells and also showed that IGFBP-2 could
function as a mitogen for PC3 cells. Our data support previous
findings, suggesting that IGFBP-2 may be a key factor in the
progression of prostate cancer (Moore et al, 2003; Chatterjee et al,
2004; Degraff et al, 2010). Using an IGF-I receptor inhibitor,
we established that although IGF-induced growth was blocked
in both cell lines, the proliferative effect of IGFBP-2 was unaffected
in the DU145 cells but negated in the PC3 cells. This confirmed
that IGFBP-2 could function either in an intrinsic, IGF-indepen-
dent manner or in an IGF-dependent manner to promote prostate
cancer cell proliferation. Enhancement of IGF-mediated effects
by IGFBPs can occur via a number of mechanisms, including
prolonging IGF half-life, and hence cell exposure or by sequester-
ing IGFs at the cell surface and increasing levels in the vicinity
of cell receptors (Perks and Holly, 2008). To date, the mechanism
by which IGFBP-2 exerts intrinsic proliferative effects in DU145
cells has not been identified (Chatterjee et al, 2004). It had
previously been reported that an antibody to IGFBP-2 inhibited
the growth of DU145 cells, indicating that IGFBP-2 produced
within the cells, had to be secreted in order to promote growth via
an autocrine, and not via an intracrine, mechanism (Chatterjee
et al, 2004). IGFBP-2 contains an integrin recognition sequence,
RGD, near the COOH C-terminus, which is the minimum
requirement for interaction with integrin receptors. It is well
established that integrin receptors contribute to survival and
proliferative signals and to the metastatic potential of tumour cells
(Schwartz, 1997; Kumar, 1998). One of the most abundant
integrins found on DU145 prostate cancer cells is the b1, whose
expression was reported to be increased with increasing Gleason
grade of prostate cancer (Murant et al, 1997; Skogseth et al,
2006). It has been shown that IGFBP-2 is able to exert intrinsic
effects on a Ewing sarcoma, and on a breast cancer, cell line by
binding to cell surfaces through its RGD recognition sequence
(Schutt et al, 2004). We have now shown that the mitogenic
actions of IGFBP-2 on DU145 cells were blocked by a short
RGD-containing disintegrin peptide or by a b1-integrin receptor
blocking antibody; suggesting that the intrinsic actions of
IGFBP-2 are mediated by binding to b-1-containing integrin
receptors. This was associated with increased phosphorylation of
PTEN without affecting total PTEN abundance; the phosphoryla-
tion of PTEN has been reported to reduce its phosphatase activity
(Uzoh et al, 2009). We recently identified IGFBP-2 as a novel
regulator of PTEN in breast cancer cells via its interaction with
integrin receptors although in those cells the abundance of PTEN
protein was reduced (Perks et al, 2007). PTEN has been shown to
inhibit integrin-mediated signalling (Gu et al, 1998), indicating a
potential feedback regulation loop. The growth inhibitory effect of
IGFBP-2 siRNA was reduced in the presence of a PTEN inhibitor,
suggesting that this growth inhibition involved increased PTEN
activity. We also found that loss of IGFBP-2 improved the
effectiveness of docetaxel-induced cell death. Chemotherapy with
docetaxel is the most effective treatment available for metastatic
castration-resistant prostate cancer. Our data show that loss of
IGFBP-2 reduced the resistance of CaP cells to docetaxel; therefore,
targeting IGFBP-2 as an adjunct to this treatment may increase the
efficacy of this drug.
Progression of prostate cancer to the development of AI, chemo-
and radioresistance remain challenging clinical problems. The
search for markers of this progression have revealed IGFBP-2 and
PTEN to be strongly associated; our findings provide a mechanistic
link between these two putative markers which identifies potential
new targets for improving therapeutic response. In PC3 cells,
which lack a functional PTEN, IGFBP-2 interestingly retained its
ability to promote growth and confer chemoresistance, but in these
cells IGFBP-2 acted in a more conventional manner via its ability
to enhance IGF-receptor activation.
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Figure 4 IGFBP-2 affects the sensitivity of CaP to docetaxel. DU145
(A) and PC3 (B) CaP cells were seeded (0.08 10
6 per well; 24-well
plates), respectively, in GM and transfected as in Figure 3B for 24h. They
were then subjected to SFM conditions for a further 24h and then treated
for 24h with docetaxel (30nM for each). Cells were then counted and
assessed for cell death. The graphs represent the mean±s.e.m. of three
experiments each repeated in triplicate. Insert (B) shows a representative
WIB for IGFBP-2 protein and RT–PCR for IGFBP-2 mRNA from PC3 cell
lysates showing effective silencing of IGFBP-2 using siRNA.
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